Evidence map›Paper›PMID 36089572›Full record

ArticleTropical medicine & international health : TM & IH2022

The second national anti-tuberculosis drug resistance survey in Tanzania, 2017-2018.

Beatrice Kemilembe Mutayoba, Julia Ershova, Eligius Lyamuya, Michael Hoelscher, Norbert Heinrich, Andrew Martin Kilale, Nyagosya Segere Range, Benard James Ngowi, Nyanda Elias Ntinginya, Saidi Mwinjuma Mfaume and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tropical medicine & international health : TM & IH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. The second national anti-tuberculosis drug resistance survey in Tanzania, 2017-2018.Tropical medicine & international health : TM & IH · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Beatrice Kemilembe MutayobaDepartment of Preventive Services, Ministry of Health National AIDS Control Program, Dodoma, Tanzania.
Julia ErshovaDivision of Global HIV and TB, Global TB Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eligius LyamuyaDepartment of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Michael HoelscherDepartment of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany.
Norbert HeinrichDepartment of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany.
Andrew Martin KilaleMuhimbili Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania.
Nyagosya Segere RangeMuhimbili Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania.
Benard James NgowiMbeya College of Health and Allied Sciences, University of Dar es Salaam, Mbeya, Tanzania.
Nyanda Elias NtinginyaNational Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania.
Saidi Mwinjuma MfaumeMuhimbili Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania.
Emmanuel NkiligiNational Tuberculosis and Leprosy Program, Department of Preventive Services, Ministry of Health, Dodoma, Tanzania.
Basra DoullaNational Tuberculosis and Leprosy Program, Central Tuberculosis Reference Laboratory, Dar es Salaam, Tanzania.
Johnson LyimoNational Tuberculosis and Leprosy Program, Department of Preventive Services, Ministry of Health, Dodoma, Tanzania.
Riziki KisongaKibong'oto Infectious Diseases Hospital, Kilimanjaro, Tanzania.
Amri KingaluNational Tuberculosis and Leprosy Program, Department of Preventive Services, Ministry of Health, Dodoma, Tanzania.
Yakobo LemaMuhimbili Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania.
Zuwena KondoNational Tuberculosis and Leprosy Program, Department of Preventive Services, Ministry of Health, Dodoma, Tanzania.
Michel PletschetteDepartment of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich, Munich, Germany.
National Institute for Medical Research · TZMinistry of Health and Social Welfare · TZLudwig-Maximilians-Universität München · DEMünchen Klinik · DECenters for Disease Control and Prevention · USKilimanjaro Christian Medical Centre · TZMbeya University of Science and Technology · TZMuhimbili University of Health and Allied Sciences · TZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the levels and patterns of resistance to first- and second-line anti-tuberculosis (TB) drugs among new and previously treated sputum smear positive pulmonary TB (PTB) patients.

methodsWe conducted a nationally representative cross-sectional facility-based survey in June 2017-July 2018 involving 45 clusters selected based on probability proportional to size. The survey aimed to determine the prevalence of anti-TB drug resistance and associated risk factors among smear positive PTB patients in Tanzania. Sputum samples were examined using smear microscopy, Xpert MTB/RIF, culture and drug susceptibility testing (DST). Logistic regression was used to account for missing data and sampling design effects on the estimates and their standard errors.

resultsWe enrolled 1557 TB patients, including 1408 (90.4%) newly diagnosed and 149 (9.6%) previously treated patients. The prevalence of multidrug-resistant TB (MDR-TB) was 0.85% [95% confidence interval (CI): 0.4-1.3] among new cases and 4.6% (95% CI: 1.1-8.2) among previously treated cases. The prevalence of Mycobacterium tuberculosis strains resistant to any of the four first-line anti-TB drugs (isoniazid, rifampicin, streptomycin and ethambutol) was 1.7% among new TB patients and 6.5% among those previously treated. Drug resistance to all first-line drugs was similar (0.1%) in new and previously treated patients. None of the isolates displayed poly-resistance or extensively drug-resistant TB (XDR-TB). The only risk factor for MDR-TB was history of previous TB treatment (odds ratio = 5.7, 95% CI: 1.9-17.2).

conclusionThe burden of MDR-TB in the country was relatively low with no evidence of XDR-TB. Given the overall small number of MDR-TB cases in this survey, it will be beneficial focusing efforts on intensified case detection including universal DST.

Indexed as

Extensively Drug-Resistant TuberculosisMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsCross-Sectional StudiesEthambutolHumansIsoniazidMicrobial Sensitivity TestsRifampinStreptomycinTanzaniaAntitubercular AgentsEthambutolIsoniazidRifampinStreptomycindrug resistanceMDR-TBsurveyTanzaniatuberculosis

Identifiers

PMID36089572
PMCPMC9826299
OpenAlexW4292162831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.